

Medincell Announces the Appointment of Dr. Sharon Mates, Dr. Charles Kunsch, and Dr. Pascal Touchon to Its Board of Directors

Medincell General Assembly held on September 11, 2025, has approved the appointments of three new independent board members: Dr Sharon Mates, Dr. Charles Kunsch, and Dr. Pascal Touchon.

- **Dr. Sharon Mates, PhD**, is the co-founder and former Chair and CEO of Intra-Cellular Therapies, a CNS-focused biotech that developed the successful drug CAPLYTA®, acquired by Johnson & Johnson for \$14.6 billion in April 2025.
- **Dr. Charles Kunsch, PhD**, is a seasoned life sciences executive with over 30 years of experience, including as former Managing Director at AbbVie Ventures, where he led investments in pioneering biotech companies.
- **Dr. Pascal Touchon, DVM**, has over 40 years of international leadership in the biopharmaceutical industry, including key roles at Novartis Oncology and Atara Biotherapeutics and current board positions at Ipsen, CDR-Life, RoslinCT, Catalym and Xylocor.

Philippe Guy, Chairman of Medincell's Board, said: *"With the election of Dr. Sharon Mates, Dr. Charles Kunsch, and Dr. Pascal Touchon, we welcome a wealth of additional experience in innovation, strategic vision, and influential networks to our Board. Their contributions will be instrumental in shaping Medincell's future by reinforcing our leadership, expanding our impact, and creating lasting value."*

Other members of Medincell's Board of Directors

- Philippe Guy (Chairman) - Former Head of BCG's Global Health Care Practice and member of BCG's Worldwide Executive Committee
- Christophe Douat - CEO of Medincell
- Elisabeth Kogan - CEO of Clexio Bioscience, former SVP at Teva where she led global generic and specialty R&D
- Tone Kvåle - CFO of Herantis Pharma, with over 25 years of biotech finance leadership
- Virginie Lleu - Senior Partner at WittKieffer, with over 30 years of experience in executive search for the pharmaceutical industry

About Dr. Mates

Sharon Mates co-founded Intra-Cellular Therapies in 2002 with Nobel Laureate Dr. Paul Greengard, building the company on his groundbreaking research into intracellular signaling to pioneer treatments for psychiatric and neurologic disorders. As Co-founder, Chairman and CEO, Dr. Mates led the development of CAPLYTA® (lumateperone), a breakthrough therapy for schizophrenia and bipolar depression, with analysts projecting peak annual sales of up to \$5 billion. Under her leadership, the company went public and grew to a market capitalization of over \$10 billion before its acquisition by Johnson & Johnson for \$14.6 billion in April 2025. Previously, for almost a decade, Dr. Mates served as President of North American Vaccine Inc., where she oversaw the development of pediatric vaccines. She holds a Ph.D. in anatomy and neuroscience and completed her postdoctoral training at Harvard Medical School and Massachusetts General Hospital. In addition to her scientific leadership as a research analyst and investment banker in the life sciences sector, she has co-founded several biotech companies and has sat on several non-profit boards. Dr. Mates was named to Forbes' "50 Over 50 – Innovation" list in recognition of her lasting impact on neuroscience and biotech innovation.

About Dr. Kunsch

Charles Kunsch is a seasoned life sciences executive and investor with over 30 years of leadership in R&D, venture capital, and biotech innovation. He served as Managing Director at AbbVie Ventures, where he led investments in many high-impact biotech companies including Prevail Therapeutics (acquired by Lilly) and Tidal Therapeutics (acquired by Sanofi) among others. Earlier in his career, he held senior scientific roles at AbbVie, AtheroGenics and Human Genome Sciences. Charles Kunsch holds a Ph.D. in Immunology from Pennsylvania State University College of Medicine and completed postdoctoral training at the Roche Institute of Molecular Biology. He currently serves as a Venture Partner at Dreavent Capital, Vice Chair of the Board at Massachusetts Biomedical Initiatives, Board of Trustees of the Penn State Research Foundation, and is a board member at Captor Therapeutics and Antiverse.

About Dr. Touchon

Pascal Touchon has 40 years of international experience in the biopharmaceutical industry, holding both operational and strategic leadership positions and serving on the boards of American and European companies. Throughout his career Pascal has been focused on transforming the lives of patients with serious medical conditions through pioneering science, teamwork, and a commitment to excellence. He is the former Global Head of Strategy and Business Development, as well as the Global Head of Cell & Gene division at Novartis Oncology, where he led the development and global launch of the first approved cell and gene therapy in the U.S and the former CEO and Chairman of the Board at Atara Biotherapeutics. Pascal Touchon currently serves as Independent Director at Ipsen, CDR-Life, and RoslinCT and Operating Partner at Jeito Capital, an investment fund dedicated to biopharmaceutical companies. Pascal holds a Doctorate in Veterinary Medicine from Paul Sabatier University (Toulouse, France) and an MBA from INSEAD (Fontainebleau, France).

The documentation of the General Assembly is available on the Medincell website.

About Medincell

Medincell is a clinical and commercial-stage biopharmaceutical licensing company developing long-acting injectable drugs in many therapeutic areas. Our innovative treatments aim to guarantee compliance with medical prescriptions, to improve the effectiveness and accessibility of medicines, and to reduce their environmental footprint. They combine active pharmaceutical ingredients with our proprietary BEPO® technology which controls the delivery of a drug at a therapeutic level for several days, weeks or months from the subcutaneous or local injection of a simple deposit of a few millimeters, entirely bioresorbable. We collaborate with leading pharmaceutical companies and foundations to improve global health through new treatment options. Based in Montpellier, Medincell currently employs more than 140 people representing more than 25 different nationalities.

www.medincell.com

Contact

David Heuzé

Head of Corporate and Financial Communications, and ESG
david.heuze@Medincell.com / +33 (0)6 83 25 21 86

Grace Kim

Chief Strategy Officer, U.S. Finance
grace.kim@medincell.com / +1 (646) 991-4023

Nicolas Mérigeau / Arthur Rouillé

Media Relations
Medincell@newcap.eu / +33 (0)1 44 71 94 94

Louis-Victor Delouvrier / Alban Dufumier

Investor Relations France
Medincell@newcap.eu / +33 (0)1 44 71 94 94

This press release may contain forward-looking statements, particularly concerning the progress of the Company's clinical trials. Although the Company considers that its forecasts are based on reasonable assumptions, any statements other than statements of historical fact that may be contained in this press release relating to future events are subject to change without notice, to factors beyond the Company's control and to the Company's financial capabilities.

These statements may include, but are not limited to, any statements beginning with, followed by or including words or expressions such as "objective", "believe", "expect", "aim", "intend", "may", "anticipate", "estimate", "plan", "project", "will", "may", "probably", "should", "could" and other words or expressions of similar meaning or used in the negative. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control which may cause actual results, performance or achievements of the Company to differ materially from those anticipated or implied by such statements.

A list and description of such risks, hazards and uncertainties can be found in the documents filed by the Company with the Autorité des Marchés Financiers (AMF) pursuant to its regulatory obligations, including in the Company's document de base, registered with the AMF on September 4, 2018 under number I. 18-062, as well as in documents and reports to be published subsequently by the Company. Furthermore, these forward-looking statements only apply as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by law, the Company undertakes no obligation to publicly update these forward-looking statements, nor to update the reasons why actual results may differ materially from those anticipated in the forward-looking statements, even if new information becomes available. The Company's updating of one or more forward-looking statements does not imply that it will or will not update these or any other forward-looking statements.

This press release is published for information purposes only. The information contained herein does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for securities of the Company in any jurisdiction whatsoever, particularly in France. Similarly, this press release does not constitute investment advice and should not be treated as such. It is not intended to address the investment objectives, financial situation or specific needs of any particular recipient. It should not be relied upon as a substitute for the exercise of your own judgement. All opinions expressed in this document are subject to change without notice. The distribution of this press release may be restricted by law in certain jurisdictions. Persons into whose possession this press release comes are required to inform themselves about and to observe any such restrictions.